PROCEPT BioRobotics Corporation Common Stock (PRCT)
Stock · NASDAQ · Health Care
$17.57as of 10/16/2026
Price chart
Active signals
PRCT Signal Track Record
How signals performed across all stocks →What PRCT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -0.9% | 47% | August 4, 2026 |
| Bollinger Band Breakout | 24 | -1.2% | 42% | September 4, 2026 |
| Bollinger Band Breakdown | 22 | -1.8% | 50% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -6.0% | 33% | January 24, 2025 |
| Any 20-session window (baseline) | -2.6% | 44% |
Computed by MarketWall from daily closing prices since June 30, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquabl…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 888
- Website
- www.procept-biorobotics.com/
Fundamentals
- 1-day range
- $17.75$18.67
- Market cap
- $1.14B
- P/E (trailing)
- —
- P/E (forward)
- -15.22
- EPS (trailing)
- $-1.95
- Dividend yield
- —
- Beta
- 0.88
- Avg. volume
- 1.43M
How PROCEPT BioRobotics Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
PROCEPT BioRobotics Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- PRCTPROCEPT BioRobotics Corporation Common Stock$17.57▼ 3.20%Market cap $1.14BP/E —$16.67$38.11
- DRTSAlpha Tau Medical Ltd. Ordinary Shares$12.29▼ 6.61%Market cap $1.14BP/E —$3.43$15.79
- IRMDiRadimed Corporation Common Stock$88.27▼ 1.23%Market cap $1.17BP/E 49.82$71.34$107.9
- BVSBioventus Inc. Class A Common Stock$13.3▼ 3.69%Market cap $1.17BP/E 21.32$6.46$15.89
- TNDMTandem Diabetes Care Inc. Common Stock$16.24▼ 1.69%Market cap $1.29BP/E —$12.26$29.65
- AORTArtivion Inc. Common Stock$21.78▼ 0.41%Market cap $1.29BP/E 117.64$19.16$48.25
- IARTIntegra LifeSciences Holdings Corporation Common Stock$13.21▼ 2.37%Market cap $1.33BP/E —$8.7$20.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics Corporation Common Stock | $1.14B | — | $17.57 | ▼ 3.20% | $16.67$38.11 |
| DRTS Alpha Tau Medical Ltd. Ordinary Shares | $1.14B | — | $12.29 | ▼ 6.61% | $3.43$15.79 |
| IRMD iRadimed Corporation Common Stock | $1.17B | 49.82 | $88.27 | ▼ 1.23% | $71.34$107.9 |
| BVS Bioventus Inc. Class A Common Stock | $1.17B | 21.32 | $13.3 | ▼ 3.69% | $6.46$15.89 |
| TNDM Tandem Diabetes Care Inc. Common Stock | $1.29B | — | $16.24 | ▼ 1.69% | $12.26$29.65 |
| AORT Artivion Inc. Common Stock | $1.29B | 117.64 | $21.78 | ▼ 0.41% | $19.16$48.25 |
| IART Integra LifeSciences Holdings Corporation Common Stock | $1.33B | — | $13.21 | ▼ 2.37% | $8.7$20.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- PROCEPT BioRobotics (PRCT) Could Be 70% Undervalued On Lawsuit And Board ChangeYahoo · 10/8/2026
- Intel downgraded, Marvell upgraded: Wall Street's top analyst callsYahoo · 10/7/2026
- Barclays Initiates Coverage On PROCEPT BioRobotics with Overweight Rating, Announces Price Target of $30benzinga · 10/7/2026
- Barclays Initiates Coverage On PROCEPT BioRobotics with Overweight Rating, Announces Price Target of $30Benzinga · 10/7/2026
- Does New Director and Discounting Lawsuit Change The Bull Case For PROCEPT BioRobotics (PRCT)?Yahoo · 10/6/2026
- THINK Surgical Appoints Rick McDowell as Vice President, SalesYahoo · 9/22/2026
Insider Activity
Insider Actions →- Mack Michael · October 2, 2026 · Grant12.2K
- Mack Michael · October 2, 2026 · Grant7.7K
- Waters Kevin · September 9, 2026 · Sale373 @ $20.95
- Nouri Alaleh · September 9, 2026 · Sale297 @ $20.95
- Templin Barry L · September 9, 2026 · Sale373 @ $20.95
- Nouri Alaleh · August 13, 2026 · Grant31.8K
- Nouri Alaleh · August 13, 2026 · Grant23.0K
- Templin Barry L · August 13, 2026 · Grant36.3K
- Templin Barry L · August 13, 2026 · Grant26.2K
- Waters Kevin · August 13, 2026 · Grant40.9K
- Waters Kevin · August 13, 2026 · Grant29.5K
- Sharma Pooja · August 13, 2026 · Grant32.7K
- Sharma Pooja · August 13, 2026 · Grant23.6K
- Wood Larry L · August 7, 2026 · Buy23.9K @ $20.85
- Garrett Mary · June 9, 2026 · Grant3.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 53.42M
- Total value held
- $1.22B
- Institutional holders
- 251
- Unknown4.36M
- Unknown3.27M
- Unknown3.09M
- Unknown2.40M
- Unknown2.16M
- Unknown1.95M
- Unknown1.72M
- Unknown1.53M
- Unknown1.46M
- Unknown1.36M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
THINK Surgical Names Rick McDowell VP of Sales
THINK Surgical, a subsidiary of PROCEPT BioRobotics, has appointed Rick McDowell as Vice President of Sales. This leadership addition is intended to support the company's commercial operations. The stock is currently trading near its 52-week low, with an average analyst target of $21.64.
THINK Surgical Names Rick McDowell VP of Sales. THINK Surgical, a subsidiary of PROCEPT BioRobotics, has appointed Rick McDowell as Vice President of Sales. This leadership addition is intended to support the company's commercial operations. The stock is currently trading near its 52-week low, with an average analyst target of $21.64.